United States Human Milk Oligosaccharides (HMO) Market to Reach USD 255.15 Million by 2030 | Key Players: Nestlé, DuPont, Glycom, Jennewein | DataM Intelligence

Leander, Texas and Tokyo, Japan - Jan.13.2026
The Global Human Milk Oligosaccharides (HMO) Market was valued at USD 196.5 million in 2022 and is projected to witness lucrative growth by reaching up to USD 850.5 million by 2030. The market is growing at a CAGR of 20.1% during the forecast period 2024-2031.

Market growth is driven by rising demand for infant nutrition that closely mimics human breast milk, increasing awareness of gut health and immune development in early life, and growing adoption of HMOs in infant formula and pediatric nutrition products. Advancements in biotechnology and fermentation processes, expanding clinical evidence supporting HMO benefits, and rising investments by infant nutrition manufacturers are further accelerating market expansion. Additionally, supportive regulatory approvals, increasing preference for premium infant formulas, and growing focus on science-backed nutritional ingredients are strengthening sustained demand for human milk oligosaccharides globally.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/human-milk-oligosaccharides-market?praveen

United States Recent Industry Developments:
✅ December 2025: U.S. infant nutrition and biotechnology companies expanded production of synthetic and fermentation-derived HMOs, supporting advanced infant formula formulations that closely mimic the functional benefits of human breast milk.

✅ November 2025: Pediatric nutrition brands launched HMO-enriched infant and toddler formulas, promoting gut health, immune development, and cognitive support in early-life nutrition.

✅ October 2025: Biotechnology firms advanced precision fermentation technologies for scalable and cost-efficient HMO production, improving purity, consistency, and regulatory compliance.

Japan Recent Industry Developments:
✅ December 2025: Japanese infant formula manufacturers incorporated multi-HMO blends into premium nutrition products, aligning with growing demand for science-backed and functional infant nutrition.

✅ November 2025: Japan-based biotech companies increased investment in fermentation-derived HMO production, ensuring high-quality supply for domestic and export markets.

✅ October 2025: Collaborations between Japanese research institutes and global nutrition firms focused on HMO research for immune modulation and gut-brain axis development.

✅ September 2025: Regulatory guidance in Japan supported innovation in advanced infant nutrition ingredients, accelerating approval and commercialization of HMO-enriched products.

Human Milk Oligosaccharides (HMO) Market: Drivers
- The market is growing due to rising demand for advanced infant nutrition solutions that closely mimic the benefits of human breast milk. Increasing adoption of HMOs in infant formula to support gut health, immune development, and cognitive growth is driving market expansion. Advancements in biotechnology, fermentation, and precision synthesis enable scalable and cost-effective HMO production. Growing awareness among parents and healthcare professionals about early-life nutrition, along with regulatory approvals in key markets, supports sustained growth of the HMO market.

Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/human-milk-oligosaccharides-market?praveen

Major Key Players :
Elicityl SA | Medolac Laboratories | Inbiose NV | Glycosyn | ZuChem | Jennewein Biotechnologie GmbH | Glycom A/S | Dextra Laboratories Limited | DuPont Nutrition & Health | Nestlé Health Science.

Market Segmentation Analysis - Human Milk Oligosaccharides (HMO)
-By Product: 2'-Fucosyllactose (2'FL) Dominates Commercial Adoption
2'-Fucosyllactose (2'FL) leads the HMO market with approximately 35% share, driven by its structural similarity to the most abundant HMO found in human breast milk and strong clinical evidence supporting immune and gut health benefits in infants. Lacto-N-neotetraose (LNnT) accounts for around 20%, supported by its complementary role in infant microbiota development and its frequent co-formulation with 2'FL in premium infant formulas. Lacto-N-tetraose (LNT) holds nearly 15%, gaining traction for its prebiotic functionality. Sialylated HMOs such as 3'SL and 6'SL together represent about 20%, driven by rising interest in cognitive development and brain health. Other HMOs, including 3'FL and emerging structures, make up the remaining 10%, reflecting ongoing R&D and pipeline expansion.

-By Type: Neutral HMOs Lead Due to Higher Stability and Scale Production
Neutral HMOs dominate with nearly 60% market share, supported by easier large-scale fermentation, higher stability, and widespread regulatory approvals, particularly for infant nutrition applications. Acidic HMOs account for around 25%, driven by increasing evidence of their role in brain development, pathogen defense, and immune modulation. Other HMO types represent approximately 15%, including complex and next-generation structures still under clinical validation and early commercialization.

-By Application: Infant Formula Remains the Core Demand Driver
Infant formula applications lead the market with approximately 65% share, as manufacturers increasingly incorporate HMOs to narrow the functional gap between formula and human breast milk. Premium and follow-on formulas are the primary adopters, particularly in developed and emerging economies. Dietary supplements account for around 15%, driven by growing adult gut health, immunity, and microbiome-focused nutrition trends. Functional food and beverages represent nearly 12%, supported by innovation in fortified dairy, nutrition drinks, and clinical nutrition products. Other applications hold about 8%, including medical nutrition and early-stage pharmaceutical research.

Regional Analysis - Human Milk Oligosaccharides (HMO) Market
North America -35% Share
North America leads the global HMO market with 35% share, driven by high adoption of premium infant formula, strong consumer awareness of infant gut health, and advanced biotechnology capabilities. The U.S. dominates regional demand due to early regulatory approvals, strong presence of HMO producers, and high spending on infant nutrition and pediatric healthcare.

Europe - 30% Share
Europe accounts for 30% share, supported by stringent infant nutrition standards, rising preference for breast-milk-like formulations, and strong demand for organic and premium infant formula. Countries such as Germany, France, the Netherlands, and Switzerland play a major role, supported by robust R&D and favorable regulatory frameworks for novel food ingredients.

Asia-Pacific - 25% Share
Asia-Pacific holds 25% share and represents the fastest-growing region, fueled by rising birth rates in select markets, increasing urbanization, and growing disposable incomes in China, India, and Southeast Asia. Expanding awareness of early-life nutrition, along with rapid growth of infant formula consumption, accelerates HMO adoption.

South America - 6% Share
South America captures 6% share, driven by growing demand for fortified infant nutrition products and gradual improvement in healthcare access. Brazil and Argentina are key markets as awareness of advanced infant nutrition ingredients continues to rise.

Middle East & Africa - 4% Share
Middle East & Africa account for 4% share, supported by increasing investments in maternal and infant healthcare and growing demand for premium infant formula in urban centers. Market growth remains moderate due to pricing sensitivity and regulatory complexities but shows long-term potential.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=human-milk-oligosaccharides-market?praveen

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praveen

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.